Refractory vitiligo improving with eculizumab

Dermatol Ther. 2020 Mar;33(2):e13233. doi: 10.1111/dth.13233. Epub 2020 Feb 10.

Authors

Sylvia A Martinez-Cabriales^{1

2

3}, Michal Bohdanowicz^{1

2}, Richard Wells^{2

4}, Neil H Shear^{1

2}

Affiliations

¹ Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
² University of Toronto, Department of Medicine, Toronto, Ontario, Canada.
³ School of Medicine and Department of Dermatology, Autonomous University of Nuevo Leon, Monterrey, Mexico.
⁴ Division of Medical Oncology and Haematology, Sunnybrook Research Institute Odette Cancer Research Program, Toronto, Ontario, Canada.

PMID: 31997487
DOI: 10.1111/dth.13233

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Hypopigmentation*
Vitiligo* / diagnosis
Vitiligo* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
eculizumab